Evidence mapPaperPMID 41668331Full record

ArticleJMIR research protocols2026

Designing a Digital Twin for the Management of Noncommunicable Diseases: Protocol for a Pilot Study and Methodology Validation.

Edgar Ross, Jason Ross, Patricia Beschler, David Guydan, Robert Jamison

Abstract read
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Edgar Ross *Atrius Healthcare, 20 Wall Street, Burlington, MA, 01803-4758, United States, 1 2164961571.ORCID http://orcid.org/0000-0002-2195-5872
Jason Ross *Department of Anesthesia, Northwestern Memorial Hospital, Chicago, IL, United States.ORCID http://orcid.org/0000-0001-7094-3096
Patricia Beschler *Department of Medicine, University of Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0001-7811-648X
David Guydan *TheraNetrix, Inc., Wellesley, MA, United States.ORCID http://orcid.org/0009-0002-1103-3742
Robert JamisonBrigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID http://orcid.org/0000-0003-1768-0906

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Noncommunicable diseases (NCDs) have become the leading cause of mortality worldwide. NCDs account for 89% of all deaths in the United States and cost the US economy more than US $47 trillion in direct and indirect expenses. NCDs also account for the main cause of disability worldwide, and the incidence is increasing. The leading NCDs include diabetes, cancer, cardiovascular disease, chronic respiratory disease, and mental health conditions. Outside of aging, NCDs are caused by modifiable behavioral risk factors that include smoking, drug and alcohol abuse, unhealthy diet, obesity, and inadequate physical activity, and treatment must be directed to all of these domains. We hypothesize that a digital twin concept can be used to personalize treatment regimens through analysis of data that allows for artificial intelligence-based decision making. Objective: This study aims to present a methodology to validate this concept, which would provide a new clinical approach toward addressing the leading cause of disability and mortality worldwide today. Methods: This study will use delta scores between treatment arms to ascertain whether that distribution was normal for each of the study variables. Parametric (eg, analysis of covariance) or nonparametric analyses will be used to examine the variables to determine the impact of digital twin efficacy over normal treatment paradigms. Results: Recruitment of participants is expected to begin 6 months after study funding has been awarded and the needed approvals have been obtained. The expected results will show that digital twin modeling using the biopsychosocial characteristics of each participant will be statistically significant, supporting using this approach for personalized medical care. Conclusions: This study can help to identify significant clinical characteristics to help mitigate the impact of NCDs through biopsychosocial treatment paradigms. This paper proposes a statistical framework to evaluate the validity of the platform's modeling in support of clinical decision making.

Indexed as

Noncommunicable DiseasesDigital HealthHumansPilot Projectsbiopsychosocial treatment paradigmdigital twinshealth risk reductionNCDnoncommunicable diseasespersonalized medicine

Identifiers

PMID41668331
PMCPMC12890778

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.